Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 171

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 171
---
30, 2023, the Company
purchased a total of approximately $46 million of U.S. Treasury Bills. All outstanding investments in U.S. Treasury Bills available-for-sale
held at June 30, 2023 matured during the three months ended September 30, 2023 and were settled, resulting in a realized gain of $223,865
recorded as a component of interest income on the accompanying statement of operations and comprehensive loss.

| 5. | Intangible Assets |

The Company’s intangible assets consist of intellectual property
acquired from LAT Pharma, Inc. and are amortized over their estimated useful lives. The following is a summary of the intangible assets
as of June 30, 2024 and 2023:

| Schedule of intangible assets  |     |   | June 30, 2024 |   |     |   | June 30, 2023 |   |
|:-------------------------------|:----|:--|--------------:|:--|:----|:--|--------------:|:--|
| Intellectual Property          |     | $ |     2,293,770 |   |     | $ |     2,293,770 |   |
| Less: Accumulated Amortization |     |   |    (1,886,052 | ) |     |   |    (1,656,675 | ) |
| Intellectual Property, Net     |     | $ |       407,718 |   |     | $ |       637,095 |   |

Amortization expense amounted to $229,377 for each
of the years ended June 30, 2024 and 2023, respectively. The Company amortizes intellectual property over the expected original useful
lives of 10years.

Estimated future amortization expense is as follows:

| Schedule of future amortization expense 
 Year ending June 30,                    
 2025                                    |     |   | 229,377 |
|:----------------------------------------|:----|:--|--------:|
| 2026                                    |     |   | 178,341 |
|                                         |     | $ | 407,718 |

| 6. | Related Party Transactions |

Equity Transactions with Acuitas

On July 15, 2022, the Company entered into a securities
purchase agreement with Acuitas Group Holdings, LLC (“Acuitas”), the Company’s largest stockholder, pursuant to which
Ac